• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Omega Therapeutics, Inc. - Common Stock (NQ: OMGA )

    0.8110 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 4,778
    Open 0.8110
    Bid (Size) 0.8109 (1)
    Ask (Size) 0.8110 (1)
    Prev. Close 0.8110
    Today's Range 0.8110 - 0.8110
    52wk Range 0.7500 - 6.300
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Omega Therapeutics Announces Successful Completion of Phase 1 Trial for Novel Epigenomic Controller, Prioritized Pipeline, Leadership Changes, and Third Quarter 2024 Financial Results
    From Omega Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga

    Performance

    YTD
    -72.69%
    -72.69%
    1 Month
    -5.48%
    -5.48%
    3 Month
    -39.02%
    -39.02%
    6 Month
    -66.49%
    -66.49%
    1 Year
    -73.58%
    -73.58%

    More News

    Read More
    Omega Therapeutics to Present Multiple Posters Highlighting Versatile Platform Capabilities at Upcoming Scientific Meetings
    From Omega Therapeutics
    Via GlobeNewswire
    A Glimpse Into The Expert Outlook On Omega Therapeutics Through 4 Analysts
    Via Benzinga
    Expert Ratings For Omega Therapeutics
    Via Benzinga
    4 Analysts Have This To Say About Omega Therapeutics
    Via Benzinga
    Omega Therapeutics Announces Publication of Epigenomic Controller OTX-2002 Preclinical Data in Nature Communications
    From Omega Therapeutics
    Via GlobeNewswire
    Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research
    From Omega Therapeutics
    Via GlobeNewswire
    Uber To Rally Over 26%? Here Are 10 Top Analyst Forecasts For Wednesday
    Via Benzinga
    How Is The Market Feeling About Omega Therapeutics?
    Via Benzinga
    OMGA Stock Earnings: Omega Therapeutics Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
    From Omega Therapeutics
    Via GlobeNewswire
    Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors
    From Omega Therapeutics
    Via GlobeNewswire
    Omega Therapeutics To Participate In Two Upcoming Investor Conferences
    From Omega Therapeutics
    Via GlobeNewswire
    Omega Therapeutics Appoints Kaan Certel, Ph.D., as Chief Business Officer
    From Omega Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Omega Therapeutics Presents New Preclinical Data at ASGCT 2024 Demonstrating Tunable and Durable Upregulation of Gene Expression with Epigenomic Controllers
    From Omega Therapeutics
    Via GlobeNewswire
    OMGA Stock Earnings: Omega Therapeutics Misses EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Omega Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress
    From Omega Therapeutics
    Via GlobeNewswire
    Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
    From Omega Therapeutics
    Via GlobeNewswire
    Omega Therapeutics Presents New Preclinical Data at AACR 2024 Supporting the Potential of Precision Epigenomic Control
    From Omega Therapeutics
    Via GlobeNewswire
    OMGA Stock Earnings: Omega Therapeutics Beats EPS, Beats Revenue for Q4 2023
    Via InvestorPlace
    Omega Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Strategic Update
    From Omega Therapeutics
    Via GlobeNewswire
    Omega Therapeutics Announces Two Poster Presentations at the American Association for Cancer Research Annual Meeting 2024
    From Omega Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.